Non-peptide glycoprotein IIb/IIIa inhibitors. 9. Centrally constrained alpha-sulfonamides are useful tools for exploring platelet receptor function

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 12, 1996, Pages 1415-1420

  Egbertson, M S ^a   Bednar, B ^a   Bednar, R A ^a   Hartman, G D ^a   Gould, R J ^a   Lynch, R J ^a   Vassallo, L M ^a   Young, S D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; L 709780; SULFONAMIDE; TIROFIBAN; UNCLASSIFIED DRUG;

ARTICLE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ORAL DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0029938704     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00242-9     Document Type: Article

References (23)

1. Philips, D. R.; Charo, I. F.; Panse, L. V. Blood 1988, 71, 831;
2. (b) Philips, D. R.; Kieffer, N. Annu. Rev. Cell Biol. 1990, 6, 329.
3. Cook, N. S.; Kottirsch, G.; Zerwes, H.-G. Drugs Fut. 1994, 19, 135.
4. Huang, T. F.; Liu, C. Z.; Ouyang, C.; Teng, C. M. Biochem. Pharmacol. 1991, 43, 1209.
5. (a) Faraday, N.; Goldschmidt-Clermont, P.; Dise, K.; Bray, P. F. J. Lab. Clin. Med. 1994, 123, 728.
6. (b) Hogan, M.; Mattson, J. C.; Estry, D. W.; Klomparens, D. Ann. N.Y. Acad. Sci. 1994, 714, 282.
7. (c) Christopoulos C.; Mackie I.; Lahiri A.; Machin S. Blood Coagulation and Fibrinolysis 1993, 4, 729.
8. (d) Tsao, P. W.; Bozarth J. M.; Jackson, S. A.; Forsythe, M. S.; Flint, S. K; Mousa, S. A. Thromb. Res. 1995, 77, 543.
9. Egbertson, M. S.; Naylor, A. M.; Hartman, G. D.; Cook, J. J.; Gould, R. J.; Holahan, M. A.; Lynch, J. J.; Lynch, R. J.; Stranieri, M. T.; Vassallo, L. M. Bioorg. Med. Chem. Lett. 1994, 4, 1835.
10. Strauss, U. P.; Vesnaver, G. J. J. Phys. Chem. 1975, 79, 1558.
11. (b) Strauss, U. P.; Schlesinger, M. S. J. Phys. Chem. 1978, 82, 1627.
12. (c) Ghiggino, K. P.; Lee, A. G.; Meech, S. R.; O'Connor, D. V.; Phillips, D. Biochemistry 1981, 20, 5381.
13. (d) Bednar, B.; Trnena, J.; Svoboda, P.; Vajda, S.; Fidler, V.; Prochazka, K. Macromolecules 1991, 24, 2054.
14. Egbertson, M. S.; Chang, C. T. C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, J. J. Jr.; Lynch R. J.; Manno, P. M.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. J. Med. Chem. 1994, 37, 2537.
15. Egbertson, M. S.; Homnick, C. F.; Hartman, G. D. Synth. Commun. 1993, 23, 703.
16. All compounds were characterized by NMR, TLC, HPLC, high-resolution mass spectroscopy and H, C, N analysis.
17. 50 determinations was ±20%.
18. 50 determinations was ±20%.
19. Bricas, E.; Kieffer, E. Biochim. Biophys. Acta 1955, 18, 358, Widlanski, T. S.; Huang, J. Tetrahedron Lett. 1992, 33, 2657.
20. Bricas, E.; Kieffer, E. Biochim. Biophys. Acta 1955, 18, 358, Widlanski, T. S.; Huang, J. Tetrahedron Lett. 1992, 33, 2657.
21. D value of 10 3.7 nM obtained in stopped-flow measurements. A single measurement is shown in Figure 2, Panel A.
22. D value of 15 (20 nM) obtained in equilibrium binding measurements using the same platelet suspension. A single measurement is shown in Figure 2, Panel B.
23. All results are expressed as the mean value ± standard deviation. (Figure 2 shows typical experiments for each type of measurements.)